Hiap Hoe Ltd. (5JK)

Market Closed

18 Aug, 09:00

SGX

0. 61

-0.01

-2.4194%

- Market Cap

- P/E Ratio

- Div Yield

1,000 Volume

- Eps

S$ 0.62

Previous Close

Add Transaction

Day Range

0.61 0.62

Year Range

0.52 0.77

Want to track 5JK and more in your Portfolio? 🎯

Get Started For Free

Summary

5JK closed today lower at S$0.61, a decrease of -2.4194% from yesterday's close, completing a monthly decrease of -6.9231% or -S$0.04. Over the past 12 months, 5JK stock gained 8.0357%.

5JK pays dividends to its shareholders, with the most recent payment made on May 29, 2026. The next estimated payment will be in In 3 months on Nov 29, 2026 for a total of S$0.01.

The last earnings report, released on Feb 25, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.

Hiap Hoe Ltd. has completed 4 stock splits, with the recent split occurring on Mar 11, 2010.

The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

5JK Chart

Hiap Hoe Ltd. (5JK) FAQ

What is the stock price today?

The current price is S$0.61.

On which exchange is it traded?

Hiap Hoe Ltd. is listed on SGX.

What is its stock symbol?

The ticker symbol is 5JK.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Hiap Hoe Ltd. ever had a stock split?

Hiap Hoe Ltd. had 4 splits and the recent split was on Mar 11, 2010.

Hiap Hoe Ltd. Profile

- Industry	- Sector	Prof. Ola S. Winqvist M.D., Ph.D. CEO	SGX Exchange	SG1U37933462 ISIN
Sweden Country	5 Employees	- Last Dividend	- Last Split	- IPO Date

Overview

ISR Immune System Regulation Holding AB (publ) is a Swedish biotech company focused on the development of immunostimulatory drugs for the treatment of chronic infectious diseases and cancer. Founded in 2007, the company has dedicated itself to advancing medical science through its innovative research into the body’s immune response. With its headquarters located in Solna, Sweden, ISR Immune System Regulation Holding operates at the forefront of immunology and therapeutic research, aiming to provide novel solutions to some of the most challenging diseases facing humanity today.

Products and Services

Covid-19 Vaccine
As part of its commitment to combating global health crises, ISR Immune System Regulation Holding AB (publ) is in the process of developing a vaccine against Covid-19. This vaccine is designed to harness the body's immune response to provide protection against the coronavirus, potentially reducing the incidence and severity of the disease.
Hepatitis B (HBV) Drugs
ISR Immune System Regulation Holding AB (publ) is also developing therapeutic solutions for Hepatitis B, a serious liver infection caused by the hepatitis B virus (HBV). These drugs aim to stimulate the immune system to more effectively fight the virus, offering hope for a better standard of care for patients living with HBV.
Human Immunodeficiency Virus (HIV) Treatments
The company's pipeline includes innovative treatments for Human Immunodeficiency Virus (HIV), focusing on immunostimulatory approaches to manage and potentially reduce the impact of this chronic disease. By targeting the immune response, these treatments endeavor to provide a novel means of improving the lives of those affected by HIV.
Oncology Drugs
In the realm of cancer therapy, ISR Immune System Regulation Holding AB (publ) is pioneering the development of oncology drugs that leverage the power of the immune system. These drugs are designed to stimulate the body's natural defenses to recognize and combat cancer cells more effectively, representing a promising avenue in cancer treatment.

Contact Information

Address: Retzius vAeg 11

Phone: 46 7 05 42 79 39

Website: https://israb.se

Blog Affiliate Program About Terms Privacy Help Contact Us